Ventrus Biosciences' (VTUS) shares collapse 61% after its Diltiazem Cream for patients with anal fissures failed to lower pain more than a placebo in a Phase III trial.
Ventrus crumbles following Diltiazem Phase III results
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs